Insulin aspart efficacy and safety compared to human soluble insulin and human premix insulin (30/70) in patients with type 2 diabetes mellitus

被引：0
|
作者：
Bretzel, RG
Medding, J
Hirschberger, S
Linn, T
机构：
[1] Univ Giessen, Dept Med 3, Giessen, Germany
[2] Novo Nordisk AS, Mainz, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
804
引用
收藏
页码：A209 / A209
页数：1
相关论文
共 50 条
  • [1] A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes
    Bretzel, RG
    Medding, J
    Arnolds, S
    Linn, T
    [J]. DIABETES CARE, 2004, 27 (05) : 1023 - 1027
  • [2] A mufti-center efficacy and safety comparison of insulin aspart, human soluble insulin and human premix insulin,(70/30) in patients with type 2 diabetes mellitus
    Bretzel, RG
    Hirschberger, S
    Medding, J
    Linn, T
    [J]. DIABETES, 2002, 51 : A93 - A93
  • [3] Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus
    Cucinotta, D.
    Caputo, S.
    Mannucci, E.
    Nicolucci, A.
    Pellegrini, F.
    Perriello, G.
    Sbraccia, P.
    [J]. MINERVA ENDOCRINOLOGICA, 2012, 37 (04) : 357 - 366
  • [4] Comparison of biphasic insulin aspart and human insulin premix in patients with Type 2 diabetes
    Itoh, Hiroshi
    Morikawa, Akizuki
    Asai, Mahito
    Nishimura, Hideo
    Atoh, Keita
    Mutou, Eiji
    Oshima, Eiji
    Iwashima, Yasunor-I
    Miura, Takanori
    Sekiguchi, Masatomo
    Tani, Mitsunori
    Haneda, Masakazu
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S65 - S65
  • [5] Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
    Aravind, S. R.
    Singh, Kiran P.
    Mogylnytska, Liliia
    Zalevskaya, Alsu G.
    Matyjaszek-Matuszek, Beata
    Wernicke-Panten, Karin
    Nguyen-Pascal, My-Lien
    Pierre, Suzanne
    Rotthaeuser, Baerbel
    Kramer, Daniel
    Mukherjee, Bhaswati
    [J]. DIABETES THERAPY, 2022, 13 (07) : 1299 - 1310
  • [6] Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin
    S. R. Aravind
    Kiran P. Singh
    Liliia Mogylnytska
    Alsu G. Zalevskaya
    Beata Matyjaszek-Matuszek
    Karin Wernicke-Panten
    My-Liên Nguyên-Pascal
    Suzanne Pierre
    Baerbel Rotthaeuser
    Daniel Kramer
    Bhaswati Mukherjee
    [J]. Diabetes Therapy, 2022, 13 : 1299 - 1310
  • [7] Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus
    Pettitt, D. J.
    Ospina, P.
    Howard, C.
    Zisser, H.
    Jovanovic, L.
    [J]. DIABETIC MEDICINE, 2007, 24 (10) : 1129 - 1135
  • [8] Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China
    Lynch, M.
    Scheijbeler, H.
    Kotchie, R.
    Neilsen, S.
    White, J.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A262 - A262
  • [9] Safety and Efficacy of Insulin Aspart and Soluble Human Insulin in Elderly Type 2 Diabetes Patients: Results from UpGrade Observational Study
    [J]. DIABETES, 2011, 60 : A138 - A138
  • [10] Cost-effectiveness of Biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting
    Aristides, M.
    Kotchie, R.
    Nielsen, C.
    Valentine, W. J.
    Scheijbeler, H.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
12345